ELEMENTS OF MOLECULAR-TARGETED CHEMOTHERAPY FOR BREAST CANCER IN THE DEVELOPMENT OF CARDIOTOXICITY BY THE TYPE OF ARTERIAL HYPERTENSION

Аннотация

The introduction of intensified schemes of polychemotherapy of a new type in the treatment of breast cancer can increase the life expectancy and recovering of the patients after the diseases. But the use of humanized monoclonal antibodies in polychemotherapy regimens has led to an increase in the number of clinical cases of cardiotoxicity. Therefore, the development of arterial hypertension while taking bevacizumab was considered as one of the main issue same as other hot debates. To evaluate the hemodynamic parameters of cardiotoxicity of targeted therapy of locally advanced and metastatic breast cancer with human recombined monoclonal antibodies. The study made it possible to establish that a significant maximum change in the hypertensive and chronotropic effect was recorded at the 3rd month of the treatment. Hypertensive and chronotropic effects decreased by the 6 th month of pharmacological correction of oncopathology, while not all randomized groups of patients managed to reach the values ​​of the parameters under consideration to the starting values.